|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910437850803321 |
|
|
Titolo |
Advances in biology and therapy of multiple myeloma . Volume 1 Basic science / / Nikhil C. Munshi, Kenneth C. Anderson, editors |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York, : Springer, c2013 |
|
|
|
|
|
|
|
ISBN |
|
1-283-84894-5 |
1-4614-4666-X |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (321 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
MunshiNikhil C |
AndersonKenneth C |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
|
|
Soggetti |
|
Bone marrow - Diseases |
Myelodysplastic syndromes |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Genomic strategies determining progressions from MGUS to Multiple Myeloma -- Prognostic implication of Genetic changes (Cytogenetics, and FISH, gains and losses of DNA by SNP array and aCGH) in risk stratification in myeloma -- Advances in MM gene expression profiling -- Growth factors in MM -- Role of Wnt signaling pathways in multiple myeloma pathogenesis -- mTOR pathway in multiple myeloma -- Jak/STAT signaling in the pathogenesis and treatment of multiple myeloma -- Role of extracellular matrix in myeloma biology -- Osteoclasts: Potential target for blocking microenvironmental support of myeloma -- Targeting the BAFF/APRIL cytokine network in multiple myeloma -- Role of Osteoblast in myeloma pathology -- Migration and homing in Multiple Myeloma -- Genes and proteins of myeloma endothelial cells to search specific targets of the tumor vasculature -- Epigenetic regulation of myeloma within its bone marrow microenvironment -- Targeting mulitple myeloma tumor angiogenesis: focus on VEGF -- Novel in vivo model in myeloma -- Index. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, |
|
|
|
|